Sarah Lonergan

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

Vinca alkaloids: Anti-vascular effects in a murine tumour

Stephen Hill, Sarah Lonergan, J. Denekamp et al. · European Journal of Cancer · 1993 · 167 citations

Vinca Alkaloids, Medicine, Pharmacology +4

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Pieter Sonneveld, Emilie Asselbergs, Sonja Zweegman et al. · Blood · 2014 · 64 citations · Full text

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

Pieter Sonneveld, Annemiek Broijl, Francesca Gay et al. · Journal of Clinical Oncology · 2019 · 35 citations

Clinical Immunology, Cell Therapy, Immunodeficiencies +23

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs et al. · Haematologica · 2019 · 34 citations · Full text